Artco / Shutterstock.com
Pharmaceutical company AstraZeneca has agreed a licensing deal with German drug maker Grünenthal centring on gout treatment drug Zurampic (lesinurad).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AstraZeneca, Grünenthal, patent, licensing, lesinurad, Zyloprim, Zurampic, Luke Miels, gout,